Mutations: TP53

Copy-number alterations: KRAS

Treatment phase: Primary

Treatment strategy: NACT

Time of sampling: Treatment naiive

Tissue site: Ascites

Paired organoid available (different treatment phase): No

Homologous recombination status: SBS3 NEG